T. Rowe Price Associates
VOR icon

T. Rowe Price Associates’s Vor Biopharma VOR Stock Holding History

T. Rowe Price Associates’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$770K Buy
+41,815
New +$633K ﹤0.01% 2435

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

T. Rowe Price Associates's VOR Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Vor Biopharma (VOR) in Q2 2026: 41,815 shares worth $770K. The stake represents ﹤0.01% of the portfolio and ranks #2435 among its holdings.

102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

  • T. Rowe Price Associates held 41,815 shares of Vor Biopharma worth $770K as of Q2 2026.
  • Vor Biopharma was a new T. Rowe Price Associates position in Q2 2026.
  • Vor Biopharma made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2435 holding.
  • 102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.